{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:59:05Z","timestamp":1788875945873,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Novartis Hellas"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-025-05839-x","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:25:36Z","timestamp":1744935936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["High long-term retention rates of Secukinumab in psoriatic arthritis and ankylosing spondylitis: a 3-year interim analysis from the observational, prospective SERENA study, in Greek patients"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5995-6187","authenticated-orcid":false,"given":"Andreas","family":"Bounas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kandyli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3214-7416","authenticated-orcid":false,"given":"Gkikas","family":"Katsifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9812-4671","authenticated-orcid":false,"given":"Dimitrios","family":"Boumpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-0975","authenticated-orcid":false,"given":"Maria G.","family":"Tektonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3151-2055","authenticated-orcid":false,"given":"Sousana","family":"Gazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0486-9179","authenticated-orcid":false,"given":"Anastasios","family":"Kotrotsios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7670-3314","authenticated-orcid":false,"given":"Lazaros I.","family":"Sakkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9561-6355","authenticated-orcid":false,"given":"Athanasios N.","family":"Georgiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loukas","family":"Settas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1900-9924","authenticated-orcid":false,"given":"Xenia","family":"Madia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Ignatiadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-2930","authenticated-orcid":false,"given":"Petros P.","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"5839_CR1","unstructured":"Arthritis Foundation. The Spondyloarthritis Family. https:\/\/www.arthritis.org\/diseases\/spondyloarthritis. Accessed December 2024."},{"key":"5839_CR2","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/acr.22831","volume":"68","author":"C Stolwijk","year":"2016","unstructured":"Stolwijk C, van Onna M, Boonen A, van Tubergen A (2016) Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis. Arthritis Care Res 68:1320\u20131331. https:\/\/doi.org\/10.1002\/acr.22831","journal-title":"Arthritis Care Res"},{"key":"5839_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1471-2474-11-98","volume":"11","author":"I Anagnostopoulos","year":"2010","unstructured":"Anagnostopoulos I, Zinzaras E, Alexiou I, Papathanasiou AA, Davas E, Koutroumpas A et al (2010) The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskelet Disord 11:98. https:\/\/doi.org\/10.1186\/1471-2474-11-98","journal-title":"BMC Musculoskelet Disord"},{"key":"5839_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","volume":"17","author":"LC Coates","year":"2017","unstructured":"Coates LC, Helliwell PS (2017) Psoriatic arthritis: state of the art review. Clin Med 17:65\u201370. https:\/\/doi.org\/10.7861\/clinmedicine.17-1-65","journal-title":"Clin Med"},{"key":"5839_CR5","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376:957\u2013970. https:\/\/doi.org\/10.1056\/NEJMra1505557","journal-title":"N Engl J Med"},{"key":"5839_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D et al (2019) Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 80:251\u201365.e19. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.027","journal-title":"J Am Acad Dermatol"},{"key":"5839_CR7","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1056\/NEJMc1609622","volume":"375","author":"JD Taurog","year":"2016","unstructured":"Taurog JD, Chhabra A, Colbert RA (2016) Ankylosing Spondylitis and Axial Spondyloarthritis. N Engl J Med 375:1303. https:\/\/doi.org\/10.1056\/NEJMc1609622","journal-title":"N Engl J Med"},{"key":"5839_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105534","volume":"90","author":"JA Walsh","year":"2023","unstructured":"Walsh JA, Ogdie A, Michaud K, Peterson S, Holdsworth EA, Karyekar CS et al (2023) Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: Findings from a real-world study in the United States and Europe. Joint Bone Spine 90:105534. https:\/\/doi.org\/10.1016\/j.jbspin.2023.105534","journal-title":"Joint Bone Spine"},{"key":"5839_CR9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1586\/14737167.2014.957679","volume":"14","author":"K Kotsis","year":"2014","unstructured":"Kotsis K, Voulgari PV, Drosos AA, Carvalho AF, Hyphantis T (2014) Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review. Expert Rev Pharmacoecon Outcomes Res 14:857\u2013872. https:\/\/doi.org\/10.1586\/14737167.2014.957679","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"5839_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A (2018) The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol 55:379\u2013390. https:\/\/doi.org\/10.1007\/s12016-018-8702-3","journal-title":"Clin Rev Allergy Immunol"},{"key":"5839_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s11926-022-01084-4","volume":"24","author":"HKJ Tam","year":"2022","unstructured":"Tam HKJ, Robinson PC, Nash P (2022) Inhibiting IL-17A and IL-17F in rheumatic disease: therapeutics help to elucidate disease mechanisms. Curr Rheumatol Rep 24:310\u2013320. https:\/\/doi.org\/10.1007\/s11926-022-01084-4","journal-title":"Curr Rheumatol Rep"},{"key":"5839_CR12","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/jcpt.13416","volume":"46","author":"C He","year":"2021","unstructured":"He C, Xue C, Zhu G, Kang P (2021) Efficacy and safety of interleukin-17 inhibitors in the treatment of chronic rheumatic diseases: A combined and updated meta-analysis. J Clin Pharm Ther 46:895\u2013906. https:\/\/doi.org\/10.1111\/jcpt.13416","journal-title":"J Clin Pharm Ther"},{"key":"5839_CR13","unstructured":"European Medicines Agency Cosentyx : EPAR - Product Information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_en.pdf. Accessed December 2024."},{"key":"5839_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/jid.2015.171","volume":"135","author":"J van den Reek","year":"2015","unstructured":"van den Reek J, Kievit W, Gniadecki R, Goeman JJ, Zweegers J, van de Kerkhof PCM et al (2015) Drug survival studies in dermatology: principles, purposes, and pitfalls. J Invest Dermatol 135:1\u20135. https:\/\/doi.org\/10.1038\/jid.2015.171","journal-title":"J Invest Dermatol"},{"key":"5839_CR15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2217\/imt-2020-0195","volume":"13","author":"SH Berg","year":"2021","unstructured":"Berg SH, Balogh EA, Ghamrawi RI, Feldman SR (2021) A review of secukinumab in psoriasis treatment. Immunotherapy 13:201\u2013216. https:\/\/doi.org\/10.2217\/imt-2020-0195","journal-title":"Immunotherapy"},{"key":"5839_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/acr2.11097","volume":"2","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S et al (2020) Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 FUTURE 1 study. ACR Open Rheumatol 2:18\u201325. https:\/\/doi.org\/10.1002\/acr2.11097","journal-title":"ACR Open Rheumatol"},{"key":"5839_CR17","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","volume":"56","author":"IB McInnes","year":"2017","unstructured":"McInnes IB, Mease PJ, Ritchlin CT, Rahman P, Gottlieb AB, Kirkham B et al (2017) Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology 56:1993\u20132003. https:\/\/doi.org\/10.1093\/rheumatology\/kex301","journal-title":"Rheumatology"},{"key":"5839_CR18","doi-asserted-by":"publisher","unstructured":"Nash P, McInnes IB, Rahman P, Gottlieb AB, Kirkham B, Ding K, et al. (2018) THU0322 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 3-year results from the phase 3 future 2 study. Annals of the Rheumatic Diseases 77:379. https:\/\/doi.org\/10.1136\/annrheumdis-2018-eular.2379","DOI":"10.1136\/annrheumdis-2018-eular.2379"},{"key":"5839_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","volume":"20","author":"P Nash","year":"2018","unstructured":"Nash P, Mease PJ, McInnes IB, Rahman P, Ritchlin CT, Blanco R et al (2018) Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther 20:47. https:\/\/doi.org\/10.1186\/s13075-018-1551-x","journal-title":"Arthritis Res Ther"},{"key":"5839_CR20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","volume":"6","author":"AJ Kivitz","year":"2019","unstructured":"Kivitz AJ, Nash P, Tahir H, Everding A, Mann H, Kaszuba A et al (2019) Efficacy and safety of subcutaneous Secukinumab 150 mg with or without loading regimen in Psoriatic Arthritis: results from the FUTURE 4 study. Rheumatol Ther 6:393\u2013407. https:\/\/doi.org\/10.1007\/s40744-019-0163-5","journal-title":"Rheumatol Ther"},{"key":"5839_CR21","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1093\/rheumatology\/kez420","volume":"59","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Mease PJ, Landew\u00e9 RBM, Rahman P, Tahir H, Singhal A et al (2019) Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Rheumatology 59:1325\u20131334. https:\/\/doi.org\/10.1093\/rheumatology\/kez420","journal-title":"Rheumatology"},{"key":"5839_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001600","volume":"7","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Landew\u00e9 R, Rahman P, Tahir H, Singhal A, Boettcher E et al (2021) Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. RMD Open 7:e001600. https:\/\/doi.org\/10.1136\/rmdopen-2021-001600","journal-title":"RMD Open"},{"key":"5839_CR23","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/s0140-6736(20)30564-x","volume":"395","author":"IB McInnes","year":"2020","unstructured":"McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P et al (2020) Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet 395:1496\u20131505. https:\/\/doi.org\/10.1016\/s0140-6736(20)30564-x","journal-title":"Lancet"},{"key":"5839_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/acr.23111","volume":"69","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Mease PJ, Reimold AM, Tahir H, Rech J, Hall S et al (2017) Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a phase iii, randomized, double-blind placebo-controlled study. Arthritis Care Res 69:347\u2013355. https:\/\/doi.org\/10.1002\/acr.23111","journal-title":"Arthritis Care Res"},{"key":"5839_CR25","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P et al (2015) Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med 373:2534\u20132548. https:\/\/doi.org\/10.1056\/NEJMoa1505066","journal-title":"N Engl J Med"},{"key":"5839_CR26","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","volume":"76","author":"J Braun","year":"2017","unstructured":"Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P et al (2017) Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 76:1070\u20131077. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209730","journal-title":"Ann Rheum Dis"},{"key":"5839_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000592","volume":"3","author":"H Marzo-Ortega","year":"2017","unstructured":"Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Delicha EM et al (2017) Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. RMD Open 3:e000592. https:\/\/doi.org\/10.1136\/rmdopen-2017-000592","journal-title":"RMD Open"},{"key":"5839_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","volume":"5","author":"AJ Kivitz","year":"2018","unstructured":"Kivitz AJ, Wagner U, Dokoupilova E, Supronik J, Martin R, Talloczy Z et al (2018) Efficacy and safety of Secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study. Rheumatology and therapy 5:447\u2013462. https:\/\/doi.org\/10.1007\/s40744-018-0123-5","journal-title":"Rheumatology and therapy"},{"key":"5839_CR29","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/jdv.16180","volume":"34","author":"M Augustin","year":"2020","unstructured":"Augustin M, Jullien D, Martin A, Peralta C (2020) Real-world evidence of secukinumab in psoriasis treatment - a meta-analysis of 43 studies. J Eur Acad Dermatol Venereol 34:1174\u20131185. https:\/\/doi.org\/10.1111\/jdv.16180","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5839_CR30","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s40744-022-00460-x","volume":"9","author":"U Kiltz","year":"2022","unstructured":"Kiltz U, Sfikakis PP, Gaffney K, Bounas A, Gullick N, Lespessailles E et al (2022) Interim 2-year analysis from SERENA: a real-world study in patients with psoriatic arthritis or ankylosing spondylitis treated with secukinumab. Rheumatol Ther 9:1129\u20131142. https:\/\/doi.org\/10.1007\/s40744-022-00460-x","journal-title":"Rheumatol Ther"},{"key":"5839_CR31","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1093\/rheumatology\/keaa825","volume":"60","author":"U Lindstr\u00f6m","year":"2021","unstructured":"Lindstr\u00f6m U, Glintborg B, Di Giuseppe D, Schj\u00f8dt J\u00f8rgensen T, Gudbjornsson B, Lederballe Gr\u00f8n K et al (2021) Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis. Rheumatology 60:3635\u20133645. https:\/\/doi.org\/10.1093\/rheumatology\/keaa825","journal-title":"Rheumatology"},{"key":"5839_CR32","doi-asserted-by":"publisher","unstructured":"Alegre-Sancho JJ, N\u00fa\u00f1ez-Monje V, Campos-Fern\u00e1ndez C, Balaguer-Trull I, Robustillo-Villarino M, Aguilar-Zamora M, et al. (2023) Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis. Front Med 10:1294247. https:\/\/doi.org\/10.3389\/fmed.2023.1294247","DOI":"10.3389\/fmed.2023.1294247"},{"key":"5839_CR33","doi-asserted-by":"publisher","unstructured":"Favalli E, Marchesoni A, Balduzzi S, Montecucco C, Lomater C, Crepaldi G, et al. (2020) FRI0273 EFFECTIVENESS AND RETENTION RATE OF SECUKINUMAB FOR PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS: REAL-LIFE DATA FROM THE ITALIAN LORHEN REGISTRY. Ann Rheumat Dis 79:722.1\u20133. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.3197","DOI":"10.1136\/annrheumdis-2020-eular.3197"},{"key":"5839_CR34","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Dorta A, Le\u00f3n-Suarez P, Pe\u00f1a S, Hern\u00e1ndez-D\u00edaz M, Rodr\u00edguez-Lozano C, Gonz\u00e1lez-D\u00e1vila E, et al. (2022) Association of gender, diagnosis, and obesity with retention rate of Secukinumab in Spondyloarthropathies: results form a multicenter real-world study. Front Med 8: 815881. https:\/\/doi.org\/10.3389\/fmed.2021.815881","DOI":"10.3389\/fmed.2021.815881"},{"key":"5839_CR35","doi-asserted-by":"publisher","unstructured":"Geale K, Lindberg I, Paulsson EC, Wennerstr\u00f6m ECM, Tj\u00e4rnlund A, Noel W, et al. (2020) Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden. Rheumatol Adv Pract 4:rkaa070. https:\/\/doi.org\/10.1093\/rap\/rkaa070","DOI":"10.1093\/rap\/rkaa070"},{"key":"5839_CR36","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1093\/rheumatology\/keaa710","volume":"60","author":"JG Letarouilly","year":"2021","unstructured":"Letarouilly JG, Flachaire B, Labadie C, Kyheng M, Cohen N, Sellam J et al (2021) Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison. Rheumatology 60:2773\u20132782. https:\/\/doi.org\/10.1093\/rheumatology\/keaa710","journal-title":"Rheumatology"},{"key":"5839_CR37","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/acr.24560","volume":"74","author":"B Michelsen","year":"2022","unstructured":"Michelsen B, Georgiadis S, Di Giuseppe D, Loft AG, Nissen MJ, Iannone F et al (2022) Real-world six- and twelve-month drug retention, remission, and response rates of Secukinumab in 2,017 patients with psoriatic arthritis in thirteen european countries. Arthritis Care Res 74:1205\u20131218. https:\/\/doi.org\/10.1002\/acr.24560","journal-title":"Arthritis Care Res"},{"key":"5839_CR38","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40744-022-00446-9","volume":"9","author":"MJ Moreno-Ramos","year":"2022","unstructured":"Moreno-Ramos MJ, Sanchez-Piedra C, Mart\u00ednez-Gonz\u00e1lez O, Rodr\u00edguez-Lozano C, P\u00e9rez-Garcia C, Freire M et al (2022) Real-world effectiveness and treatment retention of secukinumab in patients with psoriatic arthritis and axial spondyloarthritis: a descriptive observational analysis of the spanish BIOBADASER registry. Rheumatol Ther 9:1031\u20131047. https:\/\/doi.org\/10.1007\/s40744-022-00446-9","journal-title":"Rheumatol Ther"},{"key":"5839_CR39","doi-asserted-by":"publisher","unstructured":"Alonso S, Villa I, Fern\u00e1ndez S, Mart\u00edn JL, Charca L, Pino M, et al. (2021) Multicenter study of Secukinumab survival and safety in spondyloarthritis and psoriatic arthritis: SEcukinumab in Cantabria and ASTURias Study. Front Med 8:679009. https:\/\/doi.org\/10.3389\/fmed.2021.679009","DOI":"10.3389\/fmed.2021.679009"},{"key":"5839_CR40","doi-asserted-by":"crossref","unstructured":"Kiltz U, Peterlik D, Winkelmann V, Tony H-P, on behalf of the aQUILA Study Group. AB0705 AQUILA STUDY IN GERMANY \u2013 REAL WORLD ADHERENCE AND PERSISTENCE OF SECUKINUMAB TREATMENT IN ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS PATIENTS \u2013 AN INTERIM ANALYSIS. Ann Rheumat Dis 2019;78:1814\u20131815.","DOI":"10.1136\/annrheumdis-2019-eular.435"},{"key":"5839_CR41","doi-asserted-by":"crossref","unstructured":"Martinis F, Caimmi C, Foti R, Visalli E, Amato G, Ramonda R, et al. AB0761 SECUKINUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS IN REAL LIFE: AN ITALIAN EXPERIENCE. Ann Rheumatic Dis 2019;78:1848.","DOI":"10.1136\/annrheumdis-2019-eular.5443"},{"key":"5839_CR42","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/14712598.2020.1761957","volume":"20","author":"MS Chimenti","year":"2020","unstructured":"Chimenti MS, Fonti GL, Conigliaro P, Sunzini F, Scrivo R, Navarini L et al (2020) One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. Exp Opin Biol Ther 20:813\u2013821. https:\/\/doi.org\/10.1080\/14712598.2020.1761957","journal-title":"Exp Opin Biol Ther"},{"key":"5839_CR43","doi-asserted-by":"publisher","unstructured":"Ramonda R, Lorenzin M, Carriero A, Chimenti MS, Scarpa R, Marchesoni A, et al. (2021) Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. RMD Open 7:e001519. https:\/\/doi.org\/10.1136\/rmdopen-2020-001519","DOI":"10.1136\/rmdopen-2020-001519"},{"key":"5839_CR44","doi-asserted-by":"publisher","unstructured":"Sivera F, N\u00fa\u00f1ez-Monje V, Campos-Fern\u00e1ndez C, Balaguer-Trull I, Robustillo-Villarino M, Aguilar-Zamora M, et al. (2023) Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum. Front Med 10. https:\/\/doi.org\/10.3389\/fmed.2023.1156557","DOI":"10.3389\/fmed.2023.1156557"},{"key":"5839_CR45","doi-asserted-by":"publisher","unstructured":"Dougados M, Lucas J, Desfleurs E, Claudepierre P, Goupille P, Ruyssen-Witrand A, et al. (2023) Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA). RMD Open 9. https:\/\/doi.org\/10.1136\/rmdopen-2022-002802","DOI":"10.1136\/rmdopen-2022-002802"},{"key":"5839_CR46","doi-asserted-by":"publisher","unstructured":"Michelsen B, Lindstr\u00f6m U, Codreanu C, Ciurea A, Zavada J, Loft AG, et al. (2020) Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. RMD Open 6. https:\/\/doi.org\/10.1136\/rmdopen-2020-001280","DOI":"10.1136\/rmdopen-2020-001280"},{"key":"5839_CR47","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/acr.24523","volume":"74","author":"B Glintborg","year":"2022","unstructured":"Glintborg B, Lindstr\u00f6m U, Giuseppe DD, Provan SA, Gudbjornsson B, Hetland ML et al (2022) One-year treatment outcomes of secukinumab versus tumor necrosis factor inhibitors in spondyloarthritis: results from five nordic biologic registries including more than 10,000 treatment courses. Arthritis Care Res (Hoboken) 74:748\u2013758. https:\/\/doi.org\/10.1002\/acr.24523","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5839_CR48","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3389\/fmed.2020.00288","volume":"7","author":"K Klavdianou","year":"2020","unstructured":"Klavdianou K, Lazarini A, Grivas A, Tseronis D, Tsalapaki C, Rapsomaniki P et al (2020) Real life efficacy and safety of secukinumab in biologic-experienced patients with psoriatic arthritis. Front Med 7:288. https:\/\/doi.org\/10.3389\/fmed.2020.00288","journal-title":"Front Med"},{"key":"5839_CR49","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1007\/s12325-020-01352-8","volume":"37","author":"U Kiltz","year":"2020","unstructured":"Kiltz U, Sfikakis PP, Gaffney K, Sator PG, von Kiedrowski R, Bounas A et al (2020) Secukinumab use in patients with moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis in real-world setting in europe: baseline data from SERENA study. Adv Ther 37:2865\u20132883. https:\/\/doi.org\/10.1007\/s12325-020-01352-8","journal-title":"Adv Ther"},{"key":"5839_CR50","unstructured":"Bounas A, Theodoridou A, Kandili A, Boumpas D, Katsifis G, Gazi S, et al. (2022) \u0391\u0391073 - \u0395\u039d\u0394\u0399\u0391\u039c\u0395\u03a3\u0397 \u0394\u0399\u0395\u03a4\u0397\u03a3 \u0391\u039d\u0391\u039b\u03a5\u03a3\u0397 \u03a4\u0397\u03a3 \u039c\u0395\u039b\u0395\u03a4\u0397\u03a3 SERENA: \u039c\u0399\u0391 \u039c\u0395\u039b\u0395\u03a4\u0397 \u03a0\u0391\u03a1\u0391\u03a4\u0397\u03a1\u0397\u03a3\u0397\u03a3 \u03a3\u0395 \u0395\u039b\u039b\u0397\u039d\u0395\u03a3 \u0391\u03a3\u0398\u0395\u039d\u0395\u0399\u03a3 \u039c\u0395 \u03a8\u03a9\u03a1\u0399\u0391\u03a3\u0399\u039a\u0397 \u0391\u03a1\u0398\u03a1\u0399\u03a4\u0399\u0394\u0391 \u039a\u0391\u0399 \u0391\u0393\u039a\u03a5\u039b\u039f\u03a0\u039f\u0399\u0397\u03a4\u0399\u039a\u0397 \u03a3\u03a0\u039f\u039d\u0394\u03a5\u039b\u0391\u03a1\u0398\u03a1\u0399\u03a4\u0399\u0394\u0391 \u03a0\u039f\u03a5 \u0395\u039b\u0391\u0392\u0391\u039d \u0398\u0395\u03a1\u0391\u03a0\u0395\u0399\u0391 \u039c\u0395 \u03a3\u0395\u039a\u039f\u03a5\u039a\u0399\u039d\u039f\u03a5\u039c\u0391\u039c\u03a0\u0397 \u03a3\u03a4\u0397\u039d \u039a\u0391\u0398\u0397\u039c\u0395\u03a1\u0399\u039d\u0397 \u039a\u039b\u0399\u039d\u0399\u039a\u0397 \u03a0\u03a1\u0391\u039a\u03a4\u0399\u039a\u0397. 28th Panhellenic Rheumatology Congress Abstracts. Available at: https:\/\/ere.gr\/assets\/files\/synedria\/panellinio_2022\/28o-RHEUMATOLOGY_FINAL-Program-v3.pdf. Accessed December 2024."},{"key":"5839_CR51","doi-asserted-by":"publisher","unstructured":"Pons M, Georgiadis S, \u00d8stergaard M, Ahmadzay ZF, Glintborg B, Heberg J, et al. (2024) Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis. Joint Bone Spine : 105824. https:\/\/doi.org\/10.1016\/j.jbspin.2024.105824","DOI":"10.1016\/j.jbspin.2024.105824"},{"key":"5839_CR52","doi-asserted-by":"publisher","unstructured":"Gentileschi S, Cannistr\u00e0 C, Gaggiano C, Damiani A, Carli L, Benucci M, et al. (2024) Secukinumab for the treatment of axial spondyloarthritis: long-term real-life data from five italian referral centers. J Personalized Med 14. https:\/\/doi.org\/10.3390\/jpm14111105","DOI":"10.3390\/jpm14111105"},{"key":"5839_CR53","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13075-024-03401-x","volume":"26","author":"R Ramonda","year":"2024","unstructured":"Ramonda R, Lorenzin M, Chimenti MS, Atzeni F, Semeraro A, D\u2019Angelo S et al (2024) Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort. Arthritis Res Ther 26:172. https:\/\/doi.org\/10.1186\/s13075-024-03401-x","journal-title":"Arthritis Res Ther"},{"key":"5839_CR54","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jval.2018.03.013","volume":"21","author":"I Montan","year":"2018","unstructured":"Montan I, L\u00f6we B, Cella D, Mehnert A, Hinz A (2018) General population norms for the functional assessment of chronic illness therapy (FACIT)-fatigue scale. Value Health 21:1313\u20131321. https:\/\/doi.org\/10.1016\/j.jval.2018.03.013","journal-title":"Value Health"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05839-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-025-05839-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05839-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T07:45:04Z","timestamp":1747986304000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-025-05839-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":54,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["5839"],"URL":"https:\/\/doi.org\/10.1007\/s00296-025-05839-x","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]},"assertion":[{"value":"3 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A. Bounas: research grants, honorarium for educational activities and consultancy fees from Abbvie, Aenorasis, Amgen, Bausch Health, FARAN, Genesis Pharma, GSK, Janssen, MSD, Novartis, Pfizer, UCB; A. Kandyli: clinical trial investigator fees, honorarium for educational activities and consultancy fees from Vianex, Enorasis, Abbvie, Pfizer, UCB and SOBI; G. Katsifis: honorarium for educational activities and consultancy fees from Abbvie, Boehringer Ingelheim, Janssen, Galapagos, Genesis Pharma, MSD, Novartis, Pfizer and Viatris; D. Boumpas: clinical trial investigator fees, honorarium for educational activities and consultancy fees from Abbvie, AstraZeneca, GSK, Novartis, Enorasis and Lilly; M. G. Tektonidou: research grants, honorarium for educational activities and consultancy fees from GSK, UCB and Lilly; S. Gazi: clinical trial investigator fees, honorarium for educational activities and consultancy fees from Pfizer, Lilly, Faran, Elpen, Abbvie and UCB; A. Kotrotsios: clinical trial investigator fees and honorarium for educational activities from Vianex, Novartis, UCB, Amgen, Pfizer and Abbvie; L. I. Sakkas: congress support from Abbvie; A. N. Georgiadis: clinical trial investigator fees, honorarium for educational activities and consultancy fees from Faran and Aenorasis; L. Settas: clinical trial investigator fees, honorarium for educational activities and consultancy fees from PPD, Pfizer, Abbvie, Horizon, Faran, Amgen and Sanofi; X. Madia: employee of Novartis Hellas S.A.C.I.; D. Ignatiadi: employee of Novartis Hellas S.A.C.I.; P. P. Sfikakis: research grants and consultancy fees from Abbvie, Roche, Pfizer, Faran, Amgen, Janssen, Boehringer Ingelheim, Gilead, Actelion, Genesis Pharma, MSD, UCB, Enorasis, Lilly and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article\u2019s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article\u2019s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit\n                      \n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Open access"}}],"article-number":"105"}}